USA - NASDAQ:ATRC - US04963C2098 - Common Stock
The current stock price of ATRC is 32.9 USD. In the past month the price decreased by -11.46%. In the past year, price decreased by -6.08%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 26.17 | 227.29B | ||
| ISRG | INTUITIVE SURGICAL INC | 63.82 | 196.99B | ||
| BSX | BOSTON SCIENTIFIC CORP | 34.81 | 152.16B | ||
| SYK | STRYKER CORP | 27.5 | 138.48B | ||
| IDXX | IDEXX LABORATORIES INC | 54.71 | 55.19B | ||
| BDX | BECTON DICKINSON AND CO | 13.39 | 55.33B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.58 | 50.67B | ||
| RMD | RESMED INC | 24.69 | 35.68B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.94 | 33.40B | ||
| DXCM | DEXCOM INC | 31.22 | 22.77B | ||
| PODD | INSULET CORP | 72.8 | 23.42B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.11 | 17.81B |
AtriCure, Inc. engages in the development, manufacture, and sale of surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. The company is headquartered in Mason, Ohio and currently employs 1,300 full-time employees. The company went IPO on 2005-08-05. The firm's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The firm's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion.
ATRICURE INC
7555 Innovation Way
Mason OHIO 45040 US
CEO: Michael H. Carrel
Employees: 1300
Phone: 15137554100
AtriCure, Inc. engages in the development, manufacture, and sale of surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. The company is headquartered in Mason, Ohio and currently employs 1,300 full-time employees. The company went IPO on 2005-08-05. The firm's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The firm's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion.
The current stock price of ATRC is 32.9 USD. The price increased by 3.75% in the last trading session.
ATRC does not pay a dividend.
ATRC has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
15 analysts have analysed ATRC and the average price target is 52.02 USD. This implies a price increase of 58.12% is expected in the next year compared to the current price of 32.9.
ATRICURE INC (ATRC) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.25).
ATRICURE INC (ATRC) has a market capitalization of 1.64B USD. This makes ATRC a Small Cap stock.
ChartMill assigns a fundamental rating of 4 / 10 to ATRC. ATRC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months ATRC reported a non-GAAP Earnings per Share(EPS) of -0.25. The EPS increased by 69.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -5.97% | ||
| ROE | -7.83% | ||
| Debt/Equity | 0.15 |
15 analysts have analysed ATRC and the average price target is 52.02 USD. This implies a price increase of 58.12% is expected in the next year compared to the current price of 32.9.
For the next year, analysts expect an EPS growth of 40.44% and a revenue growth 15.08% for ATRC